Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials

Gou, Hao; Zhai, Yiman; Guo, Junjun

doi:10.1007/s00431-023-05186-8

Cited by 5 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results demonstrate that treatment with exenatide is associated with a reduction in body weight and BMI among pediatric patients. These findings are consistent with those of Gou H et al, whose study also showed that liraglutide use was associated with lower body weight and BMI in pediatric patients ( Gou et al, 2023 ). The results of another meta-analysis confirmed that there was no clinically significant difference in weight loss and BMI between liraglutide use and pediatric patients.…”

Section: Discussionsupporting

confidence: 93%

Exenatide for obesity in children and adolescents: Systematic review and meta-analysis

Chen,

Zou,

Zhang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Objectives: There is no curative treatment for childhood obesity. We aim to synthesize published Randomized Controlled Trials (RCTs) evidence on the efficacy of exenatide in obese children and adolescents.Methods: We conducted a comprehensive search and analysis of relevant studies in popular databases such as PubMed, Web of Science, Embase, and Cochrane Library. Our focus was on RCTs that examined the effectiveness of exenatide for treating obesity in children. We primarily assessed changes in body weight, body mass index (BMI), fasting plasma glucose (FPG), or HbA1c levels. Additionally, we considered any adverse events reported during the treatment period, with particular attention to hypoglycemia. To evaluate the quality of RCTs included in our study, we employed the Cochrane bias assessment tool.Results: Five studies met the inclusion criteria. A group of 100 children were assigned to receive treatment with exenatide. Compared with controls, exenatide therapy reduced body weight and BMI by −0.6% (95% CI −0.93, −0.27), −1.11% (95% CI −1.91, −0.31), respectively. Undesirable consequences encompass gastrointestinal symptoms, with the majority of instances being characterized by mild severity.Conclusion: Exenatide demonstrates efficacy in the treatment of pediatric and adolescent obesity.Systematic Review Registration: PROSPERO https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=413706

show abstract

Section: Discussionsupporting

confidence: 93%

Exenatide for obesity in children and adolescents: Systematic review and meta-analysis

Chen,

Zou,

Zhang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Mentias et al, 2024 A cirurgia bariátrica e as farmacoterapias com efeitos na perda de peso estão associadas a um menor risco de resultados adversos entre pacientes idosos com insificiências cardíaca (IC) e obesidade; no entanto, a utilização global permanece baixa. Gou et al, 2023 A liraglutida é segura e eficaz na redução de peso e controle glicêmico em crianças e adolescentes. Alguns tratamentos de primeira linha destas crianças e adolescentes com excesso de peso e obesidade são uma intervenção de estilo de vida com múltiplos componentes.…”

Section: Fernandes Nascimento 2022unclassified

Sibutramina E Liraglutida Na Terapêutica Da Obesidade

Braga,

Barbosa,

Cecílio

et al. 2024

Rev. Contemp.

View full text Add to dashboard Cite

A obesidade, uma condição crônica global, demanda abordagens multifatoriais para seu tratamento eficaz. Este estudo avalia o uso da sibutramina e liraglutida, destacando-se a necessidade de escolha criteriosa baseada nos perfis de risco e benefício de cada paciente. Conclusões apontam para a eficácia desses medicamentos na perda de peso, enfatizando a importância de considerar individualmente os riscos associados.

show abstract